Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland · Delayed Price · Currency is CHF 12.44
-0.64 (-4.89%)
Jun 2, 2026, 5:30 PM CET
Newron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Newron Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of CHF 46.80. The average 1-year stock price forecast is 276.21% higher than the current stock price, while the lowest is CHF 34.78 (+179.58%) and the highest is CHF 71.97 (+478.54%).
Price Target: CHF 46.80 (+276.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Newron Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates CHF 48.00 → CHF 44.00 | Buy | Reiterates | CHF 48.00 → CHF 44.00 | +253.70% | May 4, 2026 |
| Lucid Capital | Lucid Capital | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 11, 2025 |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. The data is sourced from Wall Street analysts. Data sources.